Hormonal Contraception and HIV - Technical Update
This update summarizes current evidence and the World Health Organization (WHO) revised guidance regarding the use of hormonal contraception (HC) by women at high risk of acquiring HIV.
The update lists the following guidance:
Women at high risk of HIV should not be restricted from using progestogen-only injectables.
All women who choose to use progestogen-only injectables (DMPA-IM, DMPA-SC and NET-EN) should be advised on the potential increased risk of HIV acquisition.
Women who seek family planning services should receive HIV prevention information and be advised that dual method use (condoms plus an effective contraceptive method) is the best option to prevent both sexually transmitted infection (STI)/HIV acquisition and unintended pregnancy. All women who choose to use contraceptive method
Every effort should be made to ensure that women and couples have access to a wide range of contraceptive methods through voluntary family planning services and are able to make a free and informed choice of the method that best fits their individual needs and life situation, including their HIV acquisition risk.
- Hormonal Contraceptive Eligibility for Women at High Risk of HIV- FAQs
- Contraception and HIV: What Do the Evidence and WHO Technical Statement Mean for Programs?
- Hormonal Contraception and HIV- Webinar
- Hormonal Contraception and HIV: Putting New Developments in Context
- Evidence for Contraceptive Options and HIV Outcomes (ECHO) Study
- Hormonal Contraceptive Eligibility for Women at High Risk of HIV: Guidance Statement
- Family Planning and HIV Service Integration E-Learning Course
- The ECHO Study Report
- Strategic Communication for Hormonal Contraception and HIV: An Evidence Review
- Strategic Communication Framework for Hormonal Contraceptive Methods and Potential HIV-Related Risks
March 25, 2019